skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon
According to the World Health Organisation, cardiovascular diseases, such as heart attack and stroke, are the leading cause of death globally and account for 30% of all fatalities.1 In the US alone, over 70 million adults are estimated to have high enough cholesterol levels to double their risk of heart disease2; yet numbers of new therapeutics in development for this disease area have lagged behind others such as oncology and neurology. However, an analysis of the current late stage dyslipidaemia landscape reveals that this area may be gaining traction within the industry. A few promising compounds, notably the PCSK9 inhibitors, are working their way through the pipeline, and it looks like a race to develop the next cholesterol blockbuster drug is taking shape. In this paper, we take a forensic look at this area to try to identify current trends and which near-term compounds look the most encouraging.